Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ET190L1 ARTEMIS T cells in Relapsed/Refractory B-Cell Lymphoma
NCT03415399Phase 1Completed
- Sponsor
- Eureka Therapeutics, Inc.
- Start
- Sep 2017
- Primary completion
- Dec 2020
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ET019003 in B cell lymphoma, sponsored by Eureka Therapeutics, Inc. Primary endpoints: Maximum Tolerated Dose at 24 months, Toxicity profile of ET190L1 ARTEMIS T-cell treatment at 24 months and 4 more. Started Sep 2017; status: completed.
02
Drugs
ET019003
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT03415399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03415399.